Showing results (231-240 of 777) with videos related to
Sort By:
Pageof 78
British Journal of Haematology|September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implicationsKlaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.Clinical Lymphoma & Myeloma|October 20, 2005
Emerging trends in the clinical use of bortezomib in multiple myelomaPaul G Richardson, Robert Schlossman, Constantine Mitsiades, et al.Oncotarget|October 21, 2016
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applicationsJana Jakubikova, Danka Cholujova, Teru Hideshima, et al.Blood|August 30, 2003
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysisFaith E Davies, Ann M Dring, Cheng Li, et al.Blood|February 12, 2005
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoMakoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, et al.British Journal of Haematology|December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growthHiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myelomaPierfrancesco Tassone, Paola Neri, Renate Burger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myelomaMariateresa Fulciniti, Teru Hideshima, Claudine Vermot-Desroches, et al.International Journal of Cancer|December 19, 2022
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemiaDanka Cholujova, Gabor Beke, Zachary R Hunter, et al.Molecular Cancer Therapeutics|August 31, 2014
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myelomaDiana Cirstea, Loredana Santo, Teru Hideshima, et al.Pageof 78